tirzepatide off label GLP-1 medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the use is off-label What's the deal with off-label

Understanding the complete comparison of GLP-1 programs includes verifying state compliance

lawsuit attacks not only Hims new strategy to launch a copycat pill but also goes after shots that mimic Wegovy and its sister drug Ozempic

Cellulite is most likely to appear in the fatty, fleshy areas of the body where the skin is farthest away from the bone

It doesn't work as well

self-pay adds flexibility

After Gwyneth Paltrow and neuroscientist Andrew Huberman discussed GLP-1 therapies, peptides, and the future of metabolic health on The goop Podcast , public interest in retatrutide moved from medical research circles into mainstream wellness conversations